Safety of short-term cyclosporin in atopic dermatitis
DOI:
https://doi.org/10.66344/jpad.v15i1.616Keywords:
Cyclosporin, atopic dermatitis, short termAbstract
Background Cyclosporin is an immunosuppressive drug, which is also being used in
dermatology in different indications. Although its toxicity is very high but in low dose and
for short term it can be used relatively safely.
Patients and methods 25 male and female patients within age group 15-65 (mean 27.1) were
selected. There were 11 males (44%) and 14 females (56%). The study was divided into three
periods. Pre treatment period comprising the evaluation period. Treatment period of 10 weeks
duration in which cyclosporin was given to all patients in a dose of 3-5mg/kg/day.
Fortnightly visits were scheduled in which clinical examination and laboratory profiles were
evaluated. Post-treatment follow up period of 12 weeks during which adverse effects were
monitored.
Results Serum creatinine level remained in normal range in all the patients. There was no
change in all the other laboratory parameters evaluated. The mean percentage increase over
baseline of serum creatinine concentration remained relatively stable throughout the study.
No patient was withdrawn from the study because of elevation of serum creatinine.
Conclusion Cyclosporin is safe when used in low dose and for short-term therapy.
References
1. Lauerma AI, Granlund H, Reitamo S. Use of the newer immunosuppressive agents in dermatology. Bio Drugs 1997; 8: 96-106.
2. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136-42.
3. Bornhövd E, Burgdorf W, Wollenberg
A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-43.
4. Van Joost T, Stolz E, Henle F. Efficacy of low dose cyclosporin in severe atopic skin disease [Letter]. Arch Dermatol 1987; 123: 166–7.
5. Ho V C, Griffiths E, Berth-Jones J et al. Intermittent short courses of cyclosporine micro emulsion for thelong-term management of psoriasis: A 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-51.
6. Hoyer P. Complications of cyclosporin therapy. Contrib Nephrol 1995; 114:111-23.
7. Naeyaert JM, Lachapelle JM, Degreef H et al. Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus. Dermatology 1999; 198: 145-52.
8. Harper JI, Ahmed I, Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52-8.
9. Touw CR, Hakkaart-Van Roijen L, Verboom P et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-72.
10. Jan V, Vaillant L, Bressieux JM et al. Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis. Eur J Dermatol 1999; 9: 615-7.
11. Mirmirani P, Willey A, Price V. Short course of oral cyclosporine in lichen planopilaris..J Am Acad Dermatol 2003; 49: 667-71.
12. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: A clinical and immunopathologic evaluation. J Am Acad Dermatol 1997; 36: 114-7.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Amer Ejaz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
